Product Description
Cytarabine is a pyrimidine analog and is also known as arabinosylcytosine (ARA-C). It is converted into the triphosphate form within the cell and competes with cytidine to incorporate itself in the DNA. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK557680/)
Mechanisms of Action: DNA Polymerase Inhibitor,Nucleic Acid Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Zhejiang University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 47
Highest Development Phases
Phase 3: Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Diffuse Large B-Cell Lymphoma|Histiocytosis|Hodgkin Lymphoma|Leukemia|Lymphoid Leukemia|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Myelodysplastic Syndrome|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Primary Central Nervous System Lymphoma
Phase 2: Acute Monocytic Leukemia|Biphenotypic Acute Leukemia|Mantle-Cell Lymphoma|Myeloproliferative Disorders|Preleukemia
Phase 1: Acute Myelomonocytic Leukemia|Allogeneic Stem Cell Transplant|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia,
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Venetoclax in children with relapsed AML | P3 |
Active, not recruiting |
Acute Myeloid Leukemia |
2032-02-17 |
|
| HEM-iSMART C | P2 |
Not yet recruiting |
Lymphoma, Non-Hodgkin|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia |
2031-10-01 |
|
| HEM-iSMART B | P2 |
Not yet recruiting |
Lymphoma, Non-Hodgkin|Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2031-10-01 |
|
| QuANTUM-WILD | P3 |
Recruiting |
Leukemia |
2030-06-26 |